Serum Neopterin as a Prognostic Indicator in Patients with Gastric Carcinoma

Basit Öğe Kaydı
dc.authoridKOCER, Havva Belma/0000-0002-9888-0661
dc.authoridaksaray, sebahat/0000-0002-0552-1337
dc.authorwosidKOCER, Havva Belma/IXN-8658-2023
dc.authorwosidALTUN, BULENT/I-9024-2013
dc.contributor.authorUnal, B.
dc.contributor.authorKocer, B.
dc.contributor.authorAltun, B.
dc.contributor.authorSurmeli, S.
dc.contributor.authorAksaray, S.
dc.contributor.authorBalci, M.
dc.contributor.authorOzlu, B.
dc.date.accessioned2024-08-04T20:32:13Z
dc.date.available2024-08-04T20:32:13Z
dc.date.issued2009
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: To evaluate the possible association between serum neopterin level and clinical and laboratory findings and their prognostic value of patients with gastric carcinoma. Methods: Serum samples were collected from patients (n = 38) and normal volunteers (n = 39) and stored at -80 degrees C until analyzed. Neopterin, C-reactive protein (CRP), and IL-6 concentration were measured by ELISA. The clinicopathological parameters were determined by reviewing both medical charts and pathological records. Results: Mean neopterin levels were 1.5.26 +/- 11.46 nmol/L in patients with gastric carcinoma and 9.87 +/- 2.90 nmol/L in the control group. Serum neopterin concentrations were significantly higher in patients with gastric carcinoma than in the control group. The number of patients with elevated neopterin level was significantly correlated with stage, gastric wall involvement, the number of metastatic lymph nodes, and the level of serum CRP. The mean neopterin concentrations were significantly elevated in patients older than 60 years, in the presence of venous invasion and increased metastatic lymph node number, and in patients with elevated CRP levels. Neopterin level was also correlated with overall survival as an independent prognostic indoicator. Conclusions: Serum neopterin levels were elevated in patients with advanced gastric cancer and correlated with prognostic parameters and overall survival. Moreover, neopterin measured at the time of diagnosis can be used to predict the survival of gastric carcinoma.en_US
dc.identifier.doi10.3109/08941930903410783
dc.identifier.endpage425en_US
dc.identifier.issn0894-1939
dc.identifier.issn1521-0553
dc.identifier.issue6en_US
dc.identifier.pmid20001811en_US
dc.identifier.scopus2-s2.0-72949118297en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage419en_US
dc.identifier.urihttps://doi.org/10.3109/08941930903410783
dc.identifier.urihttps://hdl.handle.net/11616/94935
dc.identifier.volume22en_US
dc.identifier.wosWOS:000273786400006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofJournal of Investigative Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectneopterinen_US
dc.subjectgastric canceren_US
dc.subjectprognosisen_US
dc.subjectsurvivalen_US
dc.subjectserumen_US
dc.titleSerum Neopterin as a Prognostic Indicator in Patients with Gastric Carcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu